Lv7
5005 积分 2021-03-26 加入
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China
3个月前
已完结
Beyond the Guided Missile Paradigm: Embracing the Complexity of Antibody-Drug Conjugates
4个月前
已完结
Abstract 3118: IBI3026, a first-in-class anti-PD-1/IL-12 fusion protein, demonstrates the potential to be a new immuno-oncology therapy by releasing the break in immune response and strongly activating T and NK cells in the tumor microenvironment
5个月前
已关闭
The New Frontier: Merging Molecular Glue Degrader and Antibody–Drug Conjugate Modalities To Overcome Strategic Challenges
6个月前
已完结
What influences the activity of Degrader−Antibody conjugates (DACs)
6个月前
已完结
Degrader–Antibody Conjugates: Emerging New Modality
6个月前
已完结
Linker Design for The Antibody Drug Conjugates: A Comprehensive Review
6个月前
已完结
Dual-payload Antibody–drug Conjugates: Taking a Dual Shot
7个月前
已完结
9MW2821, a next-generation Nectin-4 targeting antibody-drug conjugate, in patients with advanced solid tumors: a first-in-human, open label, multicenter, phase Ⅰ/Ⅱ study
7个月前
已完结
An Innovative Approach to Optimize First‐In‐Human Minimal Anticipated Biological Effect Level Based Starting Dose in Oncology Trials for Bispecific T‐Cell Engagers: Experience from A Solid Tumor Bispecific T‐Cell Engager
7个月前
已完结
皖公网安备34019202002308
